Last updated: February 20, 2026
What is NDC 70677-1263?
NDC 70677-1263 is the National Drug Code for a specific pharmaceutical product. According to available databases, this code corresponds to Palbociclib (FEZOLIN), a selective CDK4/6 inhibitor approved by the FDA for treating HR-positive, HER2-negative advanced or metastatic breast cancer. The drug is indicated for use in combination with endocrine therapy in both postmenopausal women and men.
Market Size and Demand Dynamics
Current Market Landscape
- Global Breast Cancer Market (2022): Valued at approximately $20.4 billion. Expected compound annual growth rate (CAGR): 4.2% (Fortune Business Insights, 2022).
- U.S. Market Share: Responsible for about 25% of global breast cancer revenues, driven by high diagnosis rates and advanced treatment adoption.
- Palbociclib Role: Dominates targeted therapy segments; other CDK4/6 inhibitors include Ribociclib and Abemaciclib.
Key Market Drivers
- Increasing prevalence of HR-positive breast cancer globally.
- Expanded FDA approval indications; recent label updates include early-stage breast cancer.
- Growing adoption of targeted therapies over chemotherapy.
Competitive Landscape
| Drug Name |
Manufacturer |
Approval Year |
Annual Sales (2022) |
Market Share (2022) |
| Palbociclib |
Pfizer |
2015 |
$2.8 billion |
55% |
| Ribociclib |
Novartis |
2017 |
$950 million |
20% |
| Abemaciclib |
Lilly |
2017 |
$750 million |
15% |
Revenue Trends
Palbociclib's sales increased from $1.7 billion in 2019 to $2.8 billion in 2022, reflecting persistent demand and expanded labeling.
Price Analysis and Projections
Current Pricing
- Average Wholesale Price (AWP): Roughly $10,000 per 28-day supply (per prescription).
- List Price: Similar to AWP; actual net prices often lower due to rebates and discounts.
- Reimbursement Rate: Major insurers reimburse around $9,000–$10,000 per cycle.
Pricing Factors
- Generic Entry: No generics yet; patent exclusivity until 2025.
- Market Penetration: High saturation in the U.S. and Europe.
- Pricing Trends: Slight increases (~3% annually) due to inflation and manufacturing costs.
Price Projections (2023–2027)
| Year |
Estimated Average Price per Cycle |
Notes |
| 2023 |
$10,300 |
Slight increase; trend persists |
| 2024 |
$10,600 |
Anticipated stable reimbursement policies |
| 2025 |
$11,000 |
Potential patent expiry; price pressure expected |
| 2026 |
$9,500 |
Launch of generic versions expected, reducing prices |
| 2027 |
$8,500 |
Competition intensifies, price decreases accelerate |
Impact of Patent Expiry and Generics
Patent expiry in 2025 will likely provoke price drops of approximately 20-30%, driven by generic manufacturers. Price reductions could reach as low as $6,000–$7,000 per cycle unless innovator companies maintain exclusivity through biosimilars or pediatric exclusivities.
Strategic Considerations
- Market Penetration: Continued growth possible where the drug gains approval for earlier lines of therapy or additional indications.
- Pricing Strategy: Maintaining premium pricing may be feasible through differentiation on efficacy and safety profiles.
- Generic Competition: Market share and revenues will decline post-2025; investment in lifecycle management and patent extensions may offset losses.
Summary of Key Data
- Current annual sales: $2.8 billion (2022)
- Estimated per-cycle price: approximately $10,000
- Patent expiration targeted for 2025
- Post-patent prices expected to fall to $6,000–$7,000
- Market growth rate: approximately 4.2% CAGR through 2025
Key Takeaways
- NDC 70677-1263 (Palbociclib) is a leading drug in the targeted breast cancer therapy market.
- Market size remains robust, driven by increasing breast cancer prevalence and regulatory approvals.
- Current pricing stands steady at around $10,000 per cycle, with slight annual increases.
- Entry of generics around 2025 could reduce prices by up to 30%, impacting revenue streams.
- Strategic planning should focus on lifecycle management, indication expansion, and market penetration.
FAQs
Q1: When is patent expiry for Palbociclib (NDC 70677-1263)?
A1: Expected patent expiry is in 2025, though patent extensions or additional exclusivities could alter the timeline.
Q2: How will generic entry affect the drug's price?
A2: Generic entry may lower prices by 20-30%, reducing revenues unless strategies are in place to retain market share.
Q3: Are there biosimilars or alternative formulations that could impact this drug?
A3: No biosimilars exist currently; future biosimilar development could influence pricing.
Q4: What are the key markets for this drug?
A4: The United States, Europe, and Japan are the primary markets due to high breast cancer prevalence and regulatory approvals.
Q5: How does Palbociclib compare with competitors in sales?
A5: It holds approximately 55% market share among CDK4/6 inhibitors, leading in sales with $2.8 billion in 2022.
References
- Fortune Business Insights. (2022). Breast Cancer Treatment Market Size, Share & Industry Analysis.
- IQVIA. (2022). National Prescription Audit.
- U.S. Food and Drug Administration. (2015). FDA Approval for Palbociclib.
- Statista. (2022). Oncology drug sales worldwide.
- EvaluatePharma. (2022). Oncology market report.
[1] Fortune Business Insights. (2022). Breast Cancer Treatment Market Size, Share & Industry Analysis.
[2] IQVIA. (2022). National Prescription Audit.
[3] U.S. Food and Drug Administration. (2015). FDA approval for Palbociclib.
[4] Statista. (2022). Oncology drug sales worldwide.
[5] EvaluatePharma. (2022). Oncology market report.
